ROLAND MARK RODEL DUMAGPI LAGOS

DRUG DATA
Generic Name:
PROCAINAMIDE
Trade Name:
Pronestyl
Patients Dose:
n/a

CLASSIFICATIO
N
Therapeutic:
Antiarrhythmics
(class IA)
Pregnancy Risk
Category:
C

MECHANISM OF
ACTION
Decrease
myocardial
exitability. Slows
conduction
velocity.
May
depress
myocardial
contractility

Minimum Dose:
100mg IVTT q
5mins

Therapeutic:
Suppression of
arrhythmias.

Maximum Dose:
600mg IVTT q
60mins

Onset:
immediate

Availability:
Solution
Route of
Administration:
IV, IM

Peak:
25 - 60 mins
Duration:
3 4 hrs
Half-Life:
2.5 4.7 hrs

INDICATION

CONTRADICATION

General:
Treatment
of
a
wide
variety
of
ventricular
and
atrial arrhythmias,
including:
Atrial
premature
contractions,
Premature
ventricular
contractions,
Ventricular
tachycardia,
Paroxysmal
atrial
tachycardia.
Maintenance
of
normal
sinus
rhythm
after
conversion
from
atrial fibrillation or
flutter

Contraindicated
in
hypersensitivity; AV
block;
Myasthenia
gravis;
Hypersinsitiviity
to
tarrazine (FDC yellow
dye #5; present in
some oral products)
Use
catiously
in
known
suspected
CNS disorder, renal
impairment.
Drug Interaction:
May have additive or
antagonistic effects
with
other
antiarryhtmics.
Additive
neurologic
toxicity
(confusion,
seizures)
with
lidocaine.
Antihypertensives
and
nitrates
may
potentiate
hypotensive
effect.
Potentiates
neuromuscular
blocking agents. May
partially antagonize
the
therapeutic
effects
of
anticholinesterase
agents in myasthenia
gravis.

ADVERSE/SIDE
EFFECTS
CNS:
Seizures,
dizziness,
confusion
CV: asystole,
heart block,
ventricular
arrhythmias,
hypotension
GI:
diarrhea,
anorexia, bitter
taste, nausea,
vomiting
Derm:
rashes

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
Assess for clients heart
rate.
Inform therapeutic
effect.
Check venoclysis
patency.
During:
Observe rights of
administration.
Administer drug on time.
Monitor BP closely
during administration.
Assess for patients
hypersensitivity.
Inform patient of the
possible adverse/side
effects of drug.
After:
Monitor bowel
elimination.
Check Lab values
leukocytes, eosinophils and
platelets.
Advise patient to report
for allergic reactions.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.

Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 1008 1010) 1915 Arch Street Philadelphia, PA 19103: F.A

Davis Company. DOI: www.fadavis.com

DRUG DATA
Generic Name:
HYDRALAZINE

CLASSIFICATIO
N
Therapeutic:
Antihypertensiv
e

Trade Name:
Apresoline
Patients Dose:
n/a
Minimum Dose:
5mg
Maximum Dose:
40mg
Availability:
Tablets, Injection,
Solution
Route of
Administration:
IV, IM, PO

Pharmacologic
Vasodilator
Pregnancy Risk
Category:
C

MECHANISM OF
ACTION
Direct-acting
peripheral
arteriolar
vasodilator.
Therapeutic:
Lowering of
blood pressure
in hypertensive
patients and
decreased
afterload in
patients with
CHF.
Onset:
5 - 20 mins
Peak:
15 - 30 mins
Duration:
2 6 hrs
Half-Life:
2 8 hrs

INDICATION

CONTRADICATION

General:
Moderate to severe
hypertension (with
a
diuretic).
Unlabeled
uses:
CHF unresponsive
to
conventional
therapy
with
digoxin
and
diuretics

Contraindicated
in
hypersensitivity;
Some
rpoducts
contain tartazine and
should be avoided in
patients with known
intolerance.
Use cautiously in
Cardiovascular or
cerebrovascular
disease; Severe renal
and hepatic fisease
(dose modification
may be necessary);
Drug Interaction:
Increase hypotension
with acute ingestion
of
alcohol,
other
antihypertensives, or
nitrates.
MAO
inhibitors
may
exaggerate
hypotension.
May
decrease
pressor
response
to
epinephrine. NSAIDS
may
decrease
antihypertensive
response.

ADVERSE/SIDE
EFFECTS
CNS:
dizziness,
drowsiness,
headache

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
Assess for clients heart
CV: tachycardia, rate.
agina,
Inform therapeutic
arrhythmias,
effect.
edema,
Check venoclysis
orthostatic
patency.
hypotension
During:
Observe rights of
GI:
administration.
diarrhea, nausea, Administer drug on time.
vomiting
Monitor BP closely
during administration.
Assess for patients
hypersensitivity.
Inform patient of the
possible adverse/side
effects of drug.
After:
Monitor BUN results.
Monitor liver function.
Arrange for pyridoxine if
patient develops symptoms
of peripheral neuritis.
Advised to avoid activity
that requires mental
alertness.
Notify health care

professionals if no
improvement w/in a few
days.
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 633 635) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com

DRUG DATA
Generic Name:
HYDROCORTISONE
SOIUM SUCCINATE
Trade Name:
A-hydroCort, SoluCortef
Patients Dose:
n/a
Minimum Dose:
4mg
Maximum Dose:
10mg
Availability:
Tablets, Injection,
Solution
Route of
Administration:
IV, IM, PO

CLASSIFICATIO
N
Therapeutic:
Antiasthmatics,
corticosteroid

Pharmacologic
corticosteroids
Pregnancy Risk
Category:
C

MECHANISM OF
ACTION
Replace
endogenous
cortisol
in
deficiency
states.
Have
potent
mineralocorticoi
d activity.
Therapeutic:
Suppression of
inflammation
and modification
of the normal
immune
response.
Onset:
rapid
Peak:
unknown
Duration:
unknown

INDICATION
General:
Management
adrenocortical
insufficiency.

CONTRADICATION
of

Contraindicated
in
active
untreated
infections
(maybe
used
in
patients
being
treated
for
some
forms
of
meningitits).
Use cautiously in
chronic treatment
Drug Interaction:
Increase
isk
of
hypokalemia
with
thiazide and loop
diuretics,
or
amphotericin
B.
Hypokalemia
may
increase
risk
of
digoxin toxicity.

ADVERSE/SIDE
EFFECTS
CNS:
Depression,
euphoria,
headache,
increased
intracranial
pressure,
personality
change,
psychoses,
restlessness

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
Assess for clients heart
rate.
Inform therapeutic
effect.
Check venoclysis
patency.
During:
Observe rights of
CV: hypertension administration.
Administer drug on time
GI:
(before 9AM to mimic
Peptic ulceration, normal diurnal
anorexia, nausea, corticosteroid levels).
vomiting
Monitor BP closely
during administration.
Assess for patients
hypersensitivity.
Inform patient of the
possible adverse/side
effects of drug.
After:

 Monitor BP hourly.
No virus vaccine for
patients taking this
medication.
Provide antacids before
meals to prevent peptic
ulcer.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 350 357) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com
Half-Life:
1.5 2 hrs

DRUG DATA
Generic Name:
ISOSORBIDE
MONONITRATE
Trade Name:
Apo-ISMN, IMDUR
Patients Dose:
n/a
Minimum Dose:
2.5mg
Maximum Dose:
5mg
Availability:

CLASSIFICATIO
N
Therapeutic:
antianginals

Pharmacologic
nitrates
Pregnancy Risk
Category:
C

MECHANISM OF
ACTION
Produce
vasodilation
(venous greater
than
arterial).
Decrease
left
ventricular enddiastolic
pressure
and
left ventricular
endvolume(preload)
. Net effect is
reduced
myocardial
oxygen
consumption.
Increase

INDICATION

CONTRADICATION

General:
Acute treatment of
angina attacks (SL
only). Prophylactic
management
of
angina
pectoris.
Treatment
of
chronic
CHF(unlabeled)

Contraindicated
in
hypersensitivity;
concurrent use of
sildenafil, vardenafil
or tadalafil.
Use
cautiously
in
volume
depleted
patients;
right
ventricular infarction;
hypertrophic
cardiomyopathy
Drug Interaction:
Concurrent use of
sildenafil, tadalafil, or
vardenafil may result

ADVERSE/SIDE
EFFECTS
CNS:
Dizziness,
headache

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
CV: hypotension, Assess for clients heart
tachycardia,
rate.
paradoxic
Inform therapeutic
bradycardia,
effect.
syncope
Check venoclysis
patency.
GI:
During:
nausea, vomiting Observe rights of
administration.
Administer drug on time.
Monitor BP closely
during administration.
Assess for patients pain.

Tablets, Injection,
Solution

coronary blood
flow by dilating
coronary
arteries
and
improving
collateral flow to
ischemic
regions.

Route of
Administration:
IV, IM, PO

in
significant
potentially
hypotension.

Inform patient of the

possible adverse/side
effects of drug.
After:
Monitor BP and heart
rate hourly.
Assess for patients pain
levels.
bedrest.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.

and
fatal

Therapeutic:
Relief and
prevention of
angina attacks
Onset:
unknown
Peak:
unknown
Duration:
12 hrs

Half-Life:
5 hrs
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 707 708) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com

DRUG DATA
Generic Name:
MAGNESIUM
SULFATE
Trade Name:
Elin Magnesium
Sulfate
Patients Dose:
n/a

CLASSIFICATIO
N
Therapeutic:
Mineral and
electrolyte
repalcements /
supplements

Pharmacologic
Mineral/electrol

MECHANISM OF
ACTION
Essential for the
activity of many
enzymes. Plays
an
important
role
in
neurotransmissi
on and muscular
excitability.
Therapeutic:

INDICATION

CONTRADICATION

General:
Treatment/preventi
on
of
hypomagnesemia.
Treatment
of
hypertension.
Anticonvulsant
associated severe
eclampsia,
preeclampsia,
or

Contraindicated
in
hypermagnesemia;
hypocalcemia;
Anuria; Hear block;
Use cautiously in any
degree
of
renal
insufficiency;
Digitalized patients.

ADVERSE/SIDE
EFFECTS
CNS:
Drowsiness
Respi: decreased
respiratory rate
CV: arrhythmias,
bradycardia,
hypotension

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
Assess for clients heart
rate.
Inform therapeutic
effect.
Check venoclysis
patency.

ytes

Replacements in
deficiency
states.
Resolution of
eclampsia.

During:
Observe rights of
Pregnancy Risk
administration.
Category:
Administer drug on time.
Maximum Dose:
D
Monitor BP closely
8 12g / day
during administration.
Onset:
Assess for patients pain.
Availability:
immediate
Inform patient of the
Tablets, Injection,
possible adverse/side
Solution
Peak:
effects of drug.
unknown
After:
Route of
Monitor BP and heart
Administration:
Duration:
rate hourly.
IV, IM, PO
30 mins
Monitor for Ca, Mg, K
levels.
Half-Life:
Monitor for renal
unknown
function.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 768 357) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com

CLASSIFICATIO
N
Therapeutic:
Opiod
analgesics

MECHANISM OF
ACTION
Binds to opiate
receptor in the
CNS. Alters the

Minimum Dose:
1 - 6g /day

DRUG DATA
Generic Name:
MEPERIDINE

acute nephritis.

INDICATION
General:
Moderate or severe
pain (alone or with

Drug Interaction:
Potentiate
calcium
channel blockers and
neuromuscular
blocking agents.

CONTRADICATION
Contraindicated
hypersensitivity;
hypersensitivity

in
to

GI:
diarrhea

ADVERSE/SIDE
EFFECTS
CNS: SEIZURES,
confusion,
sedation,

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug

Trade Name:
Demerol

perception
of
and response to
painful stimuli,
while producing
generalized CNS
depression.

non-opiod agent).
Anesthesia
adjunct.

bisulfites
(some
injectable products)

dysphoria,
euphoria, floating
feeling,
hallucinations,
headache,
unusual dreams.

preparation.
Assess for clients heart
rate.
Patients Dose:
Pharmacologic
Use
cautiously
in
Inform therapeutic
n/a
Opiod agonists
head
trauma;
effect.
increased ICP; severe
Check venoclysis
Minimum Dose:
Pregnancy Risk
renal,
hepatic
or
patency.
50mg
Category:
Therapeutic:
pulmonary disease
EENT: blurred
During:
c
Decrease in
vision, diplopia,
Observe rights of
Maximum Dose:
severity of pain.
Drug Interaction:
miosis.
administration.
150mg
Potentiate
calcium
Administer drug on time.
Onset:
channel blockers and Resp: respiratory Monitor BP closely
Availability:
immediate
neuromuscular
depression.
during administration.
Tablets, Injection,
blocking agents.
Assess for patients pain.
Solution
Peak:
CV: hypotension, Inform patient of the
5 7 mins
bradycardia.
possible adverse/side
Route of
effects of drug.
Administration:
Duration:
GI: constipation, After:
IV, IM, PO
2 3 hrs
nausea, vomiting. Instruct to change
position slowly.
Half-Life:
Instruct to lie down
2.5 4 hrs
when feeling nauseated.
Monitor for renal
function.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.
th
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 ed., pp. 784 357) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com

DRUG DATA
Generic Name:
METOCLOPRAMIDE
Trade Name:
Apo-Metoclop,
Clopra
Patients Dose:
n/a
Minimum Dose:
5mg
Maximum Dose:
10mg
Availability:
Tablets, Injection,
Solution
Route of
Administration:
IV, IM, PO

CLASSIFICATIO
N
Therapeutic:
antiemetics

Pregnancy Risk
Category:
B

MECHANISM OF
ACTION
Blocks
dopamine
receptors
in
chemoreceptor
trigger zone of
the
CNS.
Stimulates
motility of the
upper GI tract
and accelerates
gastric
emptying.
Therapeutic:
Decreased
nausea
and
vomiting.
Decreased
symptoms of
gastric stasis.
Onset:
1 3 min
Peak:
immediate
Duration:
1 2 hrs

INDICATION
General:
Prevention
of
chemotherapyinduced
emesis.
Treatment
of
postsurgical
and
diabetic
gastric
stasis. Facilitation
of
small
bowel
intubation
in
radiographic
procedures.
Management
of
esophagealreflux.
Treatment
and
prevention
of
postoperative
nausea
and
vomiting
when
nasogastric
suctioning
is
undesirable.
Unlabeled
uses:
Treatment
of
hiccups.
Adjunct
management
of
migraine
headaches.

Half-Life:
2.5 6 hrs
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th
Company. DOI: www.fadavis.com

NURSING
RESPONSIBILITIES
Contraindicated
in
Before:
hypersensitivity;
Check doctors order.
hypersensitivity
to
Review drug
bisulfites
(some
preparation.
injectable products)
Assess for clients heart
rate.
Use
cautiously
in
Inform therapeutic
head
trauma;
effect.
increased ICP; severe
Check venoclysis
renal,
hepatic
or
patency.
pulmonary disease
During:
Observe rights of
Drug Interaction:
CV: arrhythmias
administration.
Potentiate
calcium (supraventricular Administer drug on time.
channel blockers and tachycardia,
Monitor BP closely
neuromuscular
bradycardia),
during administration.
blocking agents.
hypertension,
Assess for patients pain.
hypotension.
Inform patient of the
possible adverse/side
GI: constipation, effects of drug.
diarrhea, dry
After:
mouth, nausea.
Instruct to change
position slowly.
Instruct to lie down
when feeling nauseated.
Keep diphenhydramine
injection ready.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.
ed., pp. 810 812) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
CONTRADICATION

ADVERSE/SIDE
EFFECTS
CNS: drowsiness,
extrapyramidal
reactions,
restlessness,
NEUROLEPTIC
MALIGNANT
SYNDROME,
anxiety,
depression,
irritability, tardive
dyskinesia.

DRUG DATA
Generic Name:
MIDAZOLAM

CLASSIFICATIO
N
Therapeutic:
Antianiety
agents

Trade Name:
Dormicum
Patients Dose:
n/a

Pharmacologic:
benzodiazepine
s

Minimum Dose:
1mg
Maximum Dose:
3.5mg
Availability:
Tablets, Injection,
Solution
Route of
Administration:
IV, IM, PO

Pregnancy Risk
Category:
B

MECHANISM OF
ACTION
Acts at many
levels of the
CNS to produce
generalized CNS
depression.
Effects may be
mediatedby
GABA,
an
inhibitory
neurotransmitte
r.
Therapeutic:
Short-term
sedation.
Postoperative
amnesia.
Onset:
1 3 min
Peak:
immediate
Duration:
1 2 hrs
Half-Life:
2.5 6 hrs

INDICATION

CONTRADICATION

General:
Provides sedation/
anxiolysis/
amnesia
during
therapeutic,
diagnostic,
or
radiographic
procedures
(conscious
sedation). Aids in
the induction of
anesthesia and as
part of balanced
anesthesia. As a
continuous
infusion, provides
sedation
of
mechanically
ventilated patients
during anesthesia
or in a critical care
setting,
Status
epilepticus.

Contraindicated
in:
Hypersensitivity;
Crosssensitivity with
other
benzodiazepinesmay
occur;
Shock;
Comatose patients or
those
with
preexisting
CNS
depression;
Uncontrolled severe
pain;
Products
containing
benzyl
alcohol should not be
used in neonates;
Use Cautiously in:
Pulmonary
disease;
CHF;
Renal
impairment; Severe
hepatic impairment;
Obese
pediatric
patients
(calculate
dose
on
the
Chronicbasis
of ideal body weight);
Drug Interaction:
Increase
CNS
depression
with
alcohol,
inantihistamines,
opioid
analgesics,

ADVERSE/SIDE
EFFECTS
CNS: agitation,
drowsiness,
excess sedation,
headache.

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
Assess for clients heart
EENT: blurred
rate.
vision.
Inform therapeutic
effect.
Resp: APNEA,
Check venoclysis
LARYNGOSPASM, patency.
RESPIRATORY
During:
DEPRESSION,
Observe rights of
bronchospasm,
administration.
coughing.
Administer drug on time.
Monitor BP closely
CV: CARDIAC
during administration.
ARREST,
Assess for patients pain.
arrhythmias.
Inform patient of the
possible adverse/side
GI: hiccups,
effects of drug.
nausea, vomiting. After:
Instruct to change
position slowly.
monitor IV site for
extravasation.
Arrange to reduce dose
if given opion analgesics.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few

and
other
sedative/hypnotics
(midazolam
dose
by3050% if used
concurrently).

days.

Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 822 825) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com

DRUG DATA
Generic Name:
MORPHINE

CLASSIFICATIO
N
Therapeutic:
Antianiety
agents

Trade Name:
none
Patients Dose:
n/a

Pharmacologic:
benzodiazepine
s

Minimum Dose:
5mg
Maximum Dose:
20mg
Availability:
Tablets, Injection,
Solution
Route of
Administration:
IV, IM, PO

Pregnancy Risk
Category:
B

MECHANISM OF
ACTION
Binds to opiate
receptors in the
CNS. Alters the
perception
of and response
to
painful
stimuli
while
producing
generalized CNS
depression.
Therapeutic:
Decrease in
severity of pain.
Onset:
rapid
Peak:
20 mins
Duration:
4 5 hrs
Half-Life:

INDICATION

CONTRADICATION

General:
Severe
Pain.
Pulmonary edema.
Pain
Associated
with MI.

Contraindicated
in:
Hypersensitivity;
Some
products
contain
tartrazine,
bisulfites, or alcohol
and
should
be
avoided in patients
with
known
hypersensitivity.
Use Cautiously in:
Head trauma;
Increased intracranial
pressure; Severe
renal, hepatic, or
pulmonary disease;
Hypothyroidism;
Adrenal insufficiency;
History of substance
abuse;
Drug Interaction:
Use with extreme
caution in patients
receiving
MAO

ADVERSE/SIDE
EFFECTS
CNS: confusion,
sedation,
dizziness,
dysphoria,
euphoria, floating
feeling,
hallucinations,
headstartache,
unusual dreams.

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
Assess for clients heart
rate.
Inform therapeutic
effect.
Check venoclysis
patency.
EENT: blurred
During:
vision,
Observe rights of
diplopia,miosis.
administration.
Administer drug on time.
Resp:
Monitor BP closely
RESPIRATORY
during administration.
DEPRESSION.
Assess for patients pain.
Inform patient of the
CV: hypotension, possible adverse/side
bradycardia.
effects of drug.
After:
GI: constipation, Instruct to change
nausea, vomiting. position slowly.
monitor IV site for
extravasation.

 Arrange to reduce dose

if given opion analgesics.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 843 847) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com
2 4 hrs

DRUG DATA
Generic Name:
MORPHINE
Trade Name:
none
Patients Dose:
n/a
Minimum Dose:
0.5mg

CLASSIFICATIO
N
Therapeutic:
Antianginals,
antihypertensiv
e

Pharmacologic:
Calcium
channel
blockers

Maximum Dose:
2.2mg
Availability:
Tablets, Injection,
Solution

Pregnancy Risk
Category:
c

MECHANISM OF
ACTION
Inhibits
the
transport
of
calcium
into
myocardial and
vascular smooth
muscle
cells,
resulting
in
inhibition
of
excitationcontraction
coupling
and
subsequent
contraction.
Therapeutic:
Systemic
vasodilation
resulting in
decreased blood

inhibitors within 14
days
prior
(may
result
in
unpredictable, severe
reactionsdecrease
initial
dose
of
morphine to 25% of
usual dose).

INDICATION

CONTRADICATION

General:
Management
of:
Hypertension,
Angina
pectoris,
Vasospastic
(Prinzmetals)
angina. Unlabeled
buses:
Management
of
CHF.

Contraindicated
in:
Hypersensitivity; Sick
sinus syndrome; 2ndor
3rd-degree
AV
block
(unless
an
artificial pacemaker
is
in
place);
BP
<90mmHg;
Advanced
aortic
stenosis.
Use
Cautiously in: Severe
hepatic impairment
Use Cautiously in:
Severe hepatic
impairment (dose
reduction
recommended);

ADVERSE/SIDE
EFFECTS
CNS: abnormal
dreams, anxiety,
confusion,
dizziness,
drowsiness,
headache,
jitteriness,
nervousness,
psychiatric
disturbances,
weakness.
EENT: blurred
vision, disturbed
equilibrium,
epistaxis,
tinnitus.
Resp: cough,

NURSING
RESPONSIBILITIES
Before:
Check doctors order.
Review drug
preparation.
Assess for clients heart
rate.
Inform therapeutic
effect.
Check venoclysis
patency.
During:
Observe rights of
administration.
Administer drug on time.
Monitor BP closely
during administration.
Assess for patients pain.
Inform patient of the
possible adverse/side

Route of
Administration:
IV, IM, PO

pressure.
Coronary
vasodilation
resulting in
decreased
frequency and
severity of
attacks of
angina.
Onset:
Within min
Peak:
45 mins

Drug Interaction:
Additive
hypotensionmay
occur
when
used
concurrently
with
fentanyl,
other
antihypertensives,
nitrates,
acute
ingestion of alcohol,
or
quinidine.
Antihypertensive
effects may beby
concurrent use of
NSAIDs. Concurrent
use
with
beta
blockers, digoxin

dyspnea,
shortness of
breath.
CV:
ARRHYTHMIAS,
CHF, peripheral
edema,
bradycardia,
chest pain,
hypotension,

effects of drug.
After:
Instruct to change
position slowly.
monitor IV site for
extravasation.
Arrange to reduce dose
if given opion analgesics.
Advised to avoid activity
that requires mental
alertness.
Notify health care
professionals if no
improvement w/in a few
days.

Duration:
50 hrs
Half-Life:
2 4 hrs
Source: Deglin J. H., Vallerand A. H. (2008). Daviss Drug Guide for Nurses. (11 th ed., pp. 879 881) 1915 Arch Street Philadelphia, PA 19103: F.A Davis
Company. DOI: www.fadavis.com